Sponsor:
Relay Therapeutics, Inc.
Code:
NCT06982521
Conditions
PIK3CA Mutation
HER2- Negative Breast Cancer
Hormone Receptor Positive Tumor
Breast Cancer
Metastatic Breast Cancer
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
RLY-2608
Capivasertib
Fulvestrant
Study Details
Eligibility Criteria
Study Design
Interventions and Outcome Measures
Central Contacts and Locations
More Information
Trial information was received from ClinicalTrials.gov and was last updated on 2025-11-09. This information was provided to ClinicalTrials.gov by Relay Therapeutics, Inc. on 2025-10-01.